Biosimilars: An Overview for Clinicians

In this educational activity, experts in oncology and immunology answer your most frequently asked questions about biosimilars, including:
-How biosimilars differ from their reference biologic and small molecule generics
-Safety, efficacy, and regulatory approval pathways
-Potential role in oncology and immunology
Sanjiv S. Agarwala, MD
Alan J. Kivitz, MD, CPI
Robert M. Rifkin, MD, FACP
Kenneth G. Saag, MD, MSc

Biosimilars: An Overview for Clinicians

In this module, Robert M. Rifkin, MD, FACP, and Kenneth G. Saag, MD, MSc, provide their expert answers to your frequently asked questions about biosimilars and their application in clinical practice.

Robert M. Rifkin, MD, FACP Kenneth G. Saag, MD, MSc Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: March 9, 2017 Expired: No longer available for credit

In this module, Sanjiv S. Agarwala, MD, and Alan J. Kivitz, MD, CPI, expand on the application of biosimilars to clinical practice by answering questions submitted by learners.

Sanjiv S. Agarwala, MD Alan J. Kivitz, MD, CPI Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: May 16, 2017 Expired: No longer available for credit

In this downloadable slideset, Sanjiv S. Agarwala, MD; Alan J. Kivitz, MD, CPI; Robert M. Rifkin, MD, FACP; and Kenneth G. Saag, MD, MSc, provide an overview of biosimilars, a new therapeutic class of drugs.

Released: March 9, 2017
Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC.
PIM Logo

Postgraduate Institute for Medicine
304 Inverness Way South, Suite 100
Englewood, CO 80112

Allison Hughes, CCMEP, Program Manager
(303) 799-1930
(303) 858-8842 (Fax)
ahughes@pimed.com
www.pimed.com

Supported by an educational grant from
Pfizer Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue